NK cell marker gene-based model shows good predictive ability in prognosis and response to immunotherapies in hepatocellular carcinoma
暂无分享,去创建一个
[1] M. Kanehisa,et al. KEGG for taxonomy-based analysis of pathways and genomes , 2022, Nucleic Acids Res..
[2] Q. Cheng,et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts , 2022, Journal of Hematology & Oncology.
[3] Sophie Curio,et al. The unique role of innate lymphoid cells in cancer and the hepatic microenvironment , 2022, Cellular & Molecular Immunology.
[4] F. Re,et al. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells , 2022, Science Immunology.
[5] T. Greten,et al. Interventional radiology meets immuno-oncology for hepatocellular carcinoma. , 2022, Journal of hepatology.
[6] K. Luo,et al. Visualization of natural killer cell-mediated killing of cancer cells at single-cell resolution in live zebrafish. , 2022, Biosensors & bioelectronics.
[7] Jakob Nikolas Kather,et al. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma. , 2022, Journal of hepatology.
[8] K. Ainslie,et al. Microparticle Delivery of a STING Agonist Enables Indirect Activation of NK Cells by Antigen-Presenting Cells. , 2022, Molecular pharmaceutics.
[9] Lin Zhang,et al. Single-Cell Transcriptomic Analysis Reveals Macrophage–Tumor Crosstalk in Hepatocellular Carcinoma , 2022, Frontiers in Immunology.
[10] K. Sartorius,et al. Resident Immune Cells of the Liver in the Tumor Microenvironment , 2022, Frontiers in Oncology.
[11] K. Yamagata,et al. NAD+ salvage governs mitochondrial metabolism, invigorating natural killer cell antitumor immunity , 2022, Hepatology.
[12] Doan Y. Dao,et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma , 2022, Nature Reviews Gastroenterology & Hepatology.
[13] Hailong Wu,et al. Liver Regeneration in Chronic Liver Injuries: Basic and Clinical Applications Focusing on Macrophages and Natural Killer Cells , 2022, Cellular and molecular gastroenterology and hepatology.
[14] T. Luedde,et al. Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. , 2022, Journal of hepatology.
[15] Aileen W. Li,et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack , 2022, Nature.
[16] É. Vivier,et al. Advancing natural killer therapies against cancer , 2022, Cell.
[17] A. Fathi,et al. Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma , 2022, Cancers.
[18] V. Mazzaferro,et al. Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.
[19] L. Altucci,et al. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma , 2021, Cells.
[20] P. Thall,et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. , 2020, The New England journal of medicine.
[21] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[22] S. Asthana,et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.
[23] F. Souza-Fonseca-Guimaraes,et al. Bench to bedside: NK cells and control of metastasis. , 2017, Clinical immunology.
[24] Ash A. Alizadeh,et al. Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.
[25] F. Marincola,et al. Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus , 2015, Journal of Translational Medicine.
[26] G. Gores,et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. , 2013, Gastroenterology.
[27] L. Moretta. NK cell-mediated immune response against cancer. , 2007, Surgical oncology.